


WHAT IS CLAIMED IS:

1 1. An analgesic/anti-inflammatory pharmaceutical
 2 dosage form which comprises an effective amount of an active
 3 ingredient selected from the group consisting of racemic 5-
 4 benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, of the
 5 formula



12 optically active forms thereof and pharmaceutically acceptable
 13 salts thereof, in combination with a pharmaceutically
 14 acceptable excipient or diluent, said dosage form being an
 15 intranasally administrable dosage form.

1 2. The dosage form of claim 1 comprising 0.5-40 mg
 2 of said active ingredient.

1 3. The dosage form of claim 2 comprising 2-20 mg of
 2 said active ingredient.

1 4. The dosage form of claim 1 comprising 5-20% of
 2 said active ingredient (weight/volume).

1 5. The dosage form of claim 1 in a single-dose
 2 form.

1 6. The dosage form of claim 1 in the form of a
 2 solution or suspension.

1 7. The dosage form of claim 1 containing 15% of
 2 said active ingredient.

1 8. The dosage form of claim 1 wherein said
 2 excipient comprises a bioadhesive.

1 9. The dosage form of claim 1 wherein said
2 excipient comprises a polymer that dissolves vehicle viscosity
3 based on temperature change, to increase said viscosity at body
4 temperature.

1 10. The dosage form of claim 1 further comprising as
2 an excipient an intranasal absorption promoter.
3

1 11. The dosage form of claim 10 wherein said
2 promoter is selected from the group consisting of POE (9)
3 lauryl alcohol and sodium glycocholate and lysophosphatidyl
4 choline.
5

1 12. A method for the treatment of inflammatory
2 processes and pain of a traumatic or pathologic origin, which
3 comprises the administration by the intranasal route of an
4 effective amount of the active ingredient 5-benzoyl-2,3-
5 dihydro-1H-pyrrolizine-1-carboxylic acid, in a racemic or
6 optically active form or in the form of a pharmaceutically
7 acceptable salt.

1 13. A method according to claim 8 wherein said
2 effective amount is within the range of 0.5-40 mg.

1 14. A method according to claim 8 wherein said
2 effective amount is within the range of 5-30 mg.

1 15. A method according to claim 8 wherein said
2 effective amount is within the range of 5-20% (weight/volume).

1 16. A method according to claim 8 wherein said
2 effective amount is within the range of 15% (weight/volume).

1 17. A method for the treatment of inflammatory
2 processes and pain of a traumatic or pathologic origin which

1 comprises the administration by the intranasal route of a
2 dosage form according to claim 1.

3

1 18. A method according to claim 17 wherein said
2 mammal is a human and wherein said effective amount is
3 sufficient to generate a plasma concentration of 5-benzoyl-2,3-
4 dihydro-1H-pyrrolizine-1-carboxylic acid within the range
5 between 0.3 and 5 mg/liter of plasma.